|  | Non-White (N=3496) | White (N=15923) | Overall (N=19419) |
| --- | --- | --- | --- |
| **Race group** |  |  |  |
| Asian | 659 (18.9%) | 0 (0%) | 659 (3.4%) |
| Black | 2,027 (58.0%) | 0 (0%) | 2,027 (10.4%) |
| Hispanic | 810 (23.2%) | 0 (0%) | 810 (4.2%) |
| White | 0 (0%) | 15,923 (100%) | 15,923 (82.0%) |
| **In-hospital mortality** |  |  |  |
| Survived | 2,832 (81.0%) | 13,057 (82.0%) | 15,889 (81.8%) |
| Died | 664 (19.0%) | 2,866 (18.0%) | 3,530 (18.2%) |
| **Discharge to hospice** |  |  |  |
| No Hospice | 3,394 (97.1%) | 15,506 (97.4%) | 18,900 (97.3%) |
| Hospice | 102 (2.9%) | 417 (2.6%) | 519 (2.7%) |
| **Admission type** |  |  |  |
| Emergency admission | 3,171 (90.7%) | 13,183 (82.8%) | 16,354 (84.2%) |
| Elective admission | 325 (9.3%) | 2,740 (17.2%) | 3,065 (15.8%) |
| **Vasopressor** |  |  |  |
| 0 | 2,159 (61.8%) | 8,624 (54.2%) | 10,783 (55.5%) |
| 1 | 1,337 (38.2%) | 7,299 (45.8%) | 8,636 (44.5%) |
| **Mechanical ventilation** |  |  |  |
| 0 | 1,982 (56.7%) | 8,887 (55.8%) | 10,869 (56.0%) |
| 1 | 1,514 (43.3%) | 7,036 (44.2%) | 8,550 (44.0%) |
| **Renal replacement therapy** |  |  |  |
| 0 | 3,106 (88.8%) | 14,949 (93.9%) | 18,055 (93.0%) |
| 1 | 390 (11.2%) | 974 (6.1%) | 1,364 (7.0%) |
| **Red blood cell transfusion** |  |  |  |
| 0 | 3,169 (90.6%) | 14,295 (89.8%) | 17,464 (89.9%) |
| 1 | 327 (9.4%) | 1,628 (10.2%) | 1,955 (10.1%) |
| **Hospital free days** |  |  |  |
| Mean (SD) | 18.9 (10.1) | 19.3 (9.98) | 19.2 (10.0) |
| Median (Q2, Q3) | 24.0 (24.0, 26.0) | 24.0 (24.0, 26.0) | 24.0 (24.0, 26.0) |
| **Ventilation free days** |  |  |  |
| Mean (SD) | 9.57 (12.6) | 10.3 (12.9) | 10.2 (12.9) |
| Median (Q2, Q3) | 0 (0, 26.0) | 0 (0, 27.0) | 0 (0, 27.0) |
| **Vasopressor free days** |  |  |  |
| Mean (SD) | 8.88 (12.6) | 11.0 (13.2) | 10.6 (13.1) |
| Median (Q2, Q3) | 0 (0, 26.0) | 0 (0, 27.0) | 0 (0, 27.0) |
| **RRT free days** |  |  |  |
| Mean (SD) | 1.91 (6.69) | 0.937 (4.69) | 1.11 (5.12) |
| Median (Q2, Q3) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) |
| **Central line-associated bloodstream infection** | 3 (0.1%) | 11 (0.1%) | 14 (0.1%) |
| **Catheter-associated urinary tract infection** | 4 (0.1%) | 17 (0.1%) | 21 (0.1%) |
| **Surgical site infection** | 11 (0.3%) | 45 (0.3%) | 56 (0.3%) |
| **Ventilator-associated pneumonia** | 23 (0.7%) | 60 (0.4%) | 83 (0.4%) |
| **Combined nosocomial infection** | 39 (1.1%) | 125 (0.8%) | 164 (0.8%) |
| **Age by group (years)** |  |  |  |
| 100 | 1 (0.0%) | 3 (0.0%) | 4 (0.0%) |
| 18 - 44 | 514 (14.7%) | 1,206 (7.6%) | 1,720 (8.9%) |
| 45 - 64 | 1,234 (35.3%) | 4,943 (31.0%) | 6,177 (31.8%) |
| 65 - 74 | 756 (21.6%) | 3,950 (24.8%) | 4,706 (24.2%) |
| 75 - 84 | 638 (18.2%) | 3,600 (22.6%) | 4,238 (21.8%) |
| 85 | 48 (1.4%) | 308 (1.9%) | 356 (1.8%) |
| 86 | 51 (1.5%) | 259 (1.6%) | 310 (1.6%) |
| 87 | 37 (1.1%) | 265 (1.7%) | 302 (1.6%) |
| 88 | 45 (1.3%) | 234 (1.5%) | 279 (1.4%) |
| 89 | 28 (0.8%) | 190 (1.2%) | 218 (1.1%) |
| 90 | 15 (0.4%) | 73 (0.5%) | 88 (0.5%) |
| 91 | 76 (2.2%) | 570 (3.6%) | 646 (3.3%) |
| 92 | 22 (0.6%) | 130 (0.8%) | 152 (0.8%) |
| 93 | 14 (0.4%) | 70 (0.4%) | 84 (0.4%) |
| 94 | 11 (0.3%) | 51 (0.3%) | 62 (0.3%) |
| 95 | 2 (0.1%) | 30 (0.2%) | 32 (0.2%) |
| 96 | 2 (0.1%) | 19 (0.1%) | 21 (0.1%) |
| 97 | 1 (0.0%) | 13 (0.1%) | 14 (0.1%) |
| 98 | 1 (0.0%) | 5 (0.0%) | 6 (0.0%) |
| 102 | 0 (0%) | 1 (0.0%) | 1 (0.0%) |
| 99 | 0 (0%) | 3 (0.0%) | 3 (0.0%) |
| **Age overall (years)** |  |  |  |
| Mean (SD) | 63.0 (17.0) | 67.8 (15.3) | 66.9 (15.8) |
| Median (Q2, Q3) | 64.5 (64.5, 76.0) | 69.0 (69.0, 79.0) | 68.0 (68.0, 79.0) |
| **Sex** |  |  |  |
| Female | 1,808 (51.7%) | 9,331 (58.6%) | 11,139 (57.4%) |
| Male | 1,688 (48.3%) | 6,592 (41.4%) | 8,280 (42.6%) |
| **SOFA categorical** |  |  |  |
| 0 - 3 | 933 (26.7%) | 4,347 (27.3%) | 5,280 (27.2%) |
| 4 - 6 | 1,229 (35.2%) | 6,083 (38.2%) | 7,312 (37.7%) |
| 7 - 10 | 905 (25.9%) | 4,001 (25.1%) | 4,906 (25.3%) |
| 11 and above | 429 (12.3%) | 1,492 (9.4%) | 1,921 (9.9%) |
| **SOFA continuous** |  |  |  |
| Mean (SD) | 6.07 (3.56) | 5.76 (3.29) | 5.82 (3.34) |
| Median (Q2, Q3) | 5.00 (5.00, 8.00) | 5.00 (5.00, 8.00) | 5.00 (5.00, 8.00) |
| **Length of stay (days)** |  |  |  |
| Mean (SD) | 13.7 (13.1) | 12.7 (11.8) | 12.9 (12.1) |
| Median (Q2, Q3) | 9.73 (9.73, 16.8) | 9.06 (9.06, 15.6) | 9.54 (9.54, 15.7) |
| **Length of stay, if survived (days)** |  |  |  |
| Mean (SD) | 14.0 (13.1) | 12.6 (11.0) | 12.8 (11.4) |
| Median (Q2, Q3) | 9.77 (9.77, 17.0) | 8.83 (8.83, 15.5) | 9.56 (9.56, 15.6) |
| Missing | 664 (19.0%) | 2866 (18.0%) | 3530 (18.2%) |
| **Length of stay, if died (days)** |  |  |  |
| Mean (SD) | 12.7 (13.0) | 13.3 (15.1) | 13.2 (14.7) |
| Median (Q2, Q3) | 9.27 (9.27, 16.2) | 9.41 (9.41, 16.6) | 9.38 (9.38, 16.6) |
| Missing | 2832 (81.0%) | 13057 (82.0%) | 15889 (81.8%) |
| **Charlson index categorical** |  |  |  |
| 0 - 3 | 752 (21.5%) | 2,966 (18.6%) | 3,718 (19.1%) |
| 4 - 6 | 1,161 (33.2%) | 6,587 (41.4%) | 7,748 (39.9%) |
| 7 - 10 | 1,279 (36.6%) | 5,338 (33.5%) | 6,617 (34.1%) |
| 11 and above | 304 (8.7%) | 1,032 (6.5%) | 1,336 (6.9%) |
| **Charlson index continuous** |  |  |  |
| Mean (SD) | 6.14 (3.21) | 5.99 (2.89) | 6.02 (2.95) |
| Median (Q2, Q3) | 6.00 (6.00, 8.00) | 6.00 (6.00, 8.00) | 6.00 (6.00, 8.00) |
| **Hypertension** |  |  |  |
| Hypertension absent | 1,072 (30.7%) | 5,443 (34.2%) | 6,515 (33.5%) |
| Hypertension present | 2,424 (69.3%) | 10,480 (65.8%) | 12,904 (66.5%) |
| **Congestive heart failure** |  |  |  |
| CHF absent | 2,267 (64.8%) | 10,503 (66.0%) | 12,770 (65.8%) |
| CHF present | 1,229 (35.2%) | 5,420 (34.0%) | 6,649 (34.2%) |
| **COPD** |  |  |  |
| COPD absent | 2,687 (76.9%) | 12,119 (76.1%) | 14,806 (76.2%) |
| COPD present | 809 (23.1%) | 3,804 (23.9%) | 4,613 (23.8%) |
| **Asthma** |  |  |  |
| Asthma absent | 3,449 (98.7%) | 15,709 (98.7%) | 19,158 (98.7%) |
| Asthma present | 47 (1.3%) | 214 (1.3%) | 261 (1.3%) |
| **Chronic kidney disease** |  |  |  |
| CKD absent | 2,826 (80.8%) | 14,258 (89.5%) | 17,084 (88.0%) |
| CKD present | 670 (19.2%) | 1,665 (10.5%) | 2,335 (12.0%) |